YRDC-IN-1
Based on 1 publication(s) in Google Scholar
YRDC-IN-1 is a blood-brain barrier-permeable YRDC inhibitor. YRDC is a key enzyme that catalyzes the formation of N6-threonylcarbamoyladenosine at position 37 of tRNA (t6A37). YRDC-IN-1 selectively inhibits the translation of ANN codon-enriched FABP7, thereby reducing lipid droplet formation, increasing ROS, and reversing the acquired resistance of GBM to Temozolomide (TMZ) (HY-17364). YRDC-IN-1 can be used for the research of glioblastoma.
For research use only. We do not sell to patients.
- Purity : 93.96%
- CAS No.: 3120494-74-5
- Formula: C22H20N2O3
- Molecular Weight:360.41
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) YRDC-IN-1
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
In Vitro
YRDC-IN-1 (HY-Q66655) potently inhibits the proliferation of human glioma stem cells (MES28) after 48 h, with an IC50 of 65.96 μM[1].
YRDC-IN-1 (70 μM; 48 h) reduces the expression of FABP7 protein in TMZ-resistant glioblastoma cells LN18-R and glioblastoma stem cells MES28, but does not affect the level of YRDC[1].
YRDC-IN-1 (70 μM; 48 h) preferentially inhibits the translation of ANN codon-enriched FABP7 in 293 T cells, and exerts a stronger inhibitory effect on the ANN-high-content FABP7 reporter gene compared with variants with low ANN content[1].
YRDC-IN-1 (70 μM) sensitizes TMZ-resistant glioblastoma cells LN18-R and glioblastoma stem cells MES28 to TMZ, while overexpression of ANN-low FABP7 reverses this effect; in LN18-R cells, the IC50 of TMZ decreases from 535.6 μM to 239.1 μM, and in MES28 cells, it decreases from 1066.0 μM to 467.8 μM[1].
YRDC-IN-1 (70 μM; 48 h) reduces lipid droplet levels in TMZ-resistant LN18-R glioblastoma cells and MES28 glioblastoma stem cells, and overexpression of ANN-low FABP7 reverses this effect[1].
YRDC-IN-1 (0-50 μM) acts synergistically with TMZ (0-600 μM) to inhibit the proliferation of TMZ-resistant LN18-R glioblastoma cells and MES28 glioblastoma stem cells, with their average ZIP synergy scores being 15.14 and 20.66, respectively[1].
YRDC-IN-1 (70 μM; 4 days) potently inhibits the proliferation of human HuH-7 hepatocellular carcinoma cells, PANC-1 pancreatic cancer cells, HCT116 colorectal cancer cells, and SGC7901 gastric cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human TMZ-resistant glioblastoma cells (LN18-R), glioblastoma stem cells (MES28)
-
Concentration:70 μM
-
Incubation Time:48 h
-
Result:Did not alter YRDC protein levels.
Significantly reduced FABP7 protein levels in both LN18-R and MES28 cells.
-
Cell Line:human hepatocellular carcinoma (HuH-7), pancreatic carcinoma (PANC-1), colorectal carcinoma (HCT116), gastric carcinoma (SGC7901) cells
-
Concentration:70 μM
-
Incubation Time:4 days
-
Result:Significantly inhibited cell proliferation in all four cancer cell lines.
Reduced relative cell viability to ~2% in HuH-7 by day 4.
Reduced relative cell viability to ~3% in PANC-1 by day 4.
Reduced relative cell viability to ~3% in HCT116 by day 4.
Reduced relative cell viability to ~3% in SGC7901 by day 4.
In Vivo
YRDC-IN-1 (10 mg/kg; i.p.; every 3-4 days; six administrations) significantly reduces MES28-derived glioblastoma tumor volume and extends mouse survival[1].
YRDC-IN-1 (10 mg/kg; i.p.; twice weekly; three weeks) is well-tolerated in healthy BALB/c-nu mice with no significant toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c-nu (5-week-old female, intracranial injection of 5,000 patient-derived GSC147 cells)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 3-4 days; six administrations
-
Result:Reduced mean tumor volume to ~20 mm3 compared to vehicle control ~60 mm3.
Extended median survival time significantly.
-
Animal Model:BALB/c-nu (5-week-old female, intracranial injection of 5,000 patient-derived MES28 cells)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; every 3-4 days; six administrations
-
Result:Reduced mean tumor volume to ~10 mm3 compared to vehicle control ~60 mm3.
Extended median survival time significantly.
-
Animal Model:BALB/c-nu (5-week-old female, tumor-free)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice weekly; three weeks
-
Result:Did not induce significant body weight loss.
Caused no obvious pathological damage in major parenchymal organs.
Chemical Information
-
CAS No. 3120494-74-5
-
Appearance Solid
-
Molecular Weight 360.41
-
Formula C22H20N2O3
-
Color Light brown to brown
-
SMILES
O=C(N1CCC2(CC1)OCC3=C2C=CC=C3)C4=CC=C(C5=CC=CN=C5)O4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Oncogene
Targeting YRDC blocks codon-biased FABP7 translation and lipid droplet formation to overcome chemoresistance in glioblastoma. [Abstract]2026 Jun;45(22):2155-2170. PMID: 42014887
Protocols
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
YRDC-IN-1 Related Classifications
HY-Q66655 Related Classifications
Powered by Bioz
Keywords
- YRDC-IN-1
- 3120494-74-5
- DNA/RNA Synthesis
- Reactive Oxygen Species (ROS)
- blood-brain-barrier
- lipid droplets
- FABP7
- human glioblastoma stem cells
- YRDC
- reactive oxygen species
- tRNA-modifying enzymes
- LN18-R TMZ-resistant glioblastoma cells
- glioblastoma patient-derived orthotopic xenograft models
- glioblastoma
- Inhibitor
- inhibitor
- inhibit